Moderna, Inc.'s stock plummets as challenges mount, including vaccine skepticism, competitive pressures, and the RFK ...
Moderna stock is undervalued with a $97 price target, strong COVID-19 revenue, promising pipeline, and long-term growth. Read ...
Moderna’s top executives have sought to reassure investors they will be able to carry out the comeback plans announced in ...
He rose to prominence during the COVID-19 pandemic by criticising the effectiveness of the Pfizer and Moderna vaccines and their ... could potentially turn drug approval and access processes ...
Marty Makary, an outspoken critic of the nation’s food and drug regulator, stands to shake up the FDA’s standards in science ...
As the biopharma industry braces for a second term under President-elect Donald Trump, speculation is swirling around the ...
It was later granted full FDA approval in August 2021 for people ages 16 and older. Pfizer’s and Moderna's vaccine has been updated over time to target currently circulating variants ...
Moderna has secured FDA approval for its respiratory syncytial virus (RSV) vaccine, giving it a chance to generate revenue from a second product as sales of its Spikevax COVID-19 shot have slumped.
We recently compiled a list of the 10 Most Promising Cancer Stocks According to Hedge Funds. In this article, we are going to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback